Key Contacts

contact details for our global offices
email: info@orb.group
UK: +44 203 519 2229
USA: +1 650 252 0002
Sweden: +46 852 500 200
Turkey: +90 212 705 5468
UAE: +971 509 385 718

Recent News

Latest Tweets

UDDS – Universal Drug Delivery System

ORB Group > UDDS – Universal Drug Delivery System
Universal Drug Delivery System (UDDS)
Universal Drug Delivery System (UDDS) is a proprietary smart drug delivery system developed by one of ORB Incubator's start-up companies, Panaomics. UDDS is an entirely new nano-material based drug delivery system that is capable of transporting any drug that is currently available on the market to anywhere in the body. This alone is expected to have substantial impact to almost any field of medicine. However, its true merit as a unique system comes from the fact that the drug delivery is: highly targeted, extremely long-lasting and fully trackable.
Its highly targeted nature will allow the drugs to actively seek out target cells (such as cancer cells) and surgically delivers the drugs to any location where it is required. This will address one of the long-standing challenges of drug therapy where many of the highly effective drugs are toxic to healthy cells and will cause harm as collateral damage (side- effects). Therefore, by programming the drug carriers to target specific cells one could drastically reduce the said side-effects.
Pipelines
Brand name
Active Ingredient
Indications
Market (billions)
PANARit®
Rituximab
Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia
$7.78
PANABeva®
Bevacizumab
Colorectal, lung, kidney, and glioblastoma
$6.75
PANATras®
Trastuzumab
Breast, oesophageal and gastric
$6.56
PANAIma®
Imatinib
Leukaemia and gastrointestinal stromal tumours
$4.69
PANAPeg®
Pegfilgrastim
Febrile neutropenia
$4.39
PANALena®
Lenalidomide
Multiple myeloma, mantle cell lymphoma and myelodysplastic
$4.28
PANAPeme®
Pemetrexed
Lung
$2.70
PANABort®
Bortezomib
Multiple myeloma and mantle cell lymphoma
$2.61
PANACetux®
Cetuximab
Colorectal, head and neck
$1.87
PANAAbira®
Abiraterone
Prostate
$1.70
PANADox®
Doxorubicin
Breast, ovary, prostate, stomach, thyroid, lung and liver
$0.81
PANARos®
Rosuvastatin
Cardiovascular diseases and high cholesterol
$6.21
PANAAtro®
Atorvastatin
Cardiovascular disease, hypercholesterolemia and dyslipidemia
$3.94
PANAOlmes®
Olmesartan
Hypertension and cardiovascular diseases
$2.44
PANAIrbes®
Irbesartan
Nephropathy, diabetic nephropathy and hypertension
$1.92
PANAVals®
Valsartan
Hypertension, Congestive Heart Failure and Post-MI Therapy
$4.41
PANAHoFH®
Ezetimibe
Primary Hyperlipidemia, and HoFH
$1.74
Benefits
  • Universal, it could carry almost any drug currently in production

  • Robust, it is nanoparticle-based and thus it is much more resilient to damages.

  • No optimisation required when changing the drug it carries due to its simple structure.

  • Long shelf life since it is nanoparticle-based.

  • No special storage requirement as it is nanoparticle based.

  • Reduced cost of production as one type of carrier could carry multiple drugs.

  • Reduced research time to add new drugs to the carrier as the chemistry is already established.

  • Cheap, the nano-carriers are mass produced.

  • FDA approval friendly, as the drugs are being ‘enhanced’ and are not a new chemical entity (NCE).

  • Long-lasting, once injected the drugs could last for 30+ days.

  • Fully customisable, the carriers could be programmed to act in a certain manner such as traceability and cancer cell targeting.

Advantages
  • Reduce healthcare worker workload, nurses will need to only inject the patients once a month.

  • Fully and constantly traceable.

  • Remove patient responsibility, the patients do not need to worry about forgetting to take the drug or lose them.

  • Reduce antibiotic resistance increase of pathogens by ensuring the patient finished their course.

  • Reduce drug flow into the black market, a large portion of the black-market drugs are prescription drugs and by having to receive the drug at the doctor’s practice and not leaving them in the hands of patients one could reduce the risk of misuse.

  • The staff does not require retraining as the base drug that UDDS is enhancing is already known in the healthcare industry.

  • It is able to target almost any part of the body.

  • Minimise side effect as it is slowly introducing the drug with no drug introduction spike.

Redacted for patent process by Marks & Clerk, further details to be disclosed upon patent approval
WordPress Themes